Provexis PLC - Grant of Options and Warrants
Provexis plc
('Provexis' or the 'Company')
Grant of Options and Warrants
Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces today that it has granted a total of 56,000,000 options (the 'Options') under the Provexis 2005 Share Option Scheme and 58,730,000 warrants (the 'Warrants') over ordinary shares of
The Options and the Warrants have been granted following close dialogue between the Company and its larger shareholders.
The Options and the Warrants are subject to performance criteria (including share price appreciation) and they are exercisable, subject to vesting, between
Following the grant of 30,000,000 Options to
|
Director |
No. of options granted |
Existing no. of Options held |
Total no. of options over Ordinary Shares ('Total Options')
|
Total Options as a percentage of the Company's issued share capital |
|
|
30,000,000 |
52,000,000 |
82,000,000 |
3.50% |
Following the issue of the Options and the Warrants: (i) the total number of new Ordinary Shares under share options which could be issued if all of the performance criteria are met is 234,500,000 Ordinary Shares, representing 10.0 per cent. of the Company's issued share capital; and (ii) the total number of new Ordinary Shares under warrants which could be issued if all of the performance criteria are met is 58,730,000 Ordinary Shares, representing 2.50 per cent. of the Company's issued share capital.
Related Party transaction
The grant of Options to
For further information please contact:
|
Provexis plc
|
Tel: 07490 391888 |
|
Allenby Capital Limited (Nominated Adviser and Broker) |
Tel: 020 3328 5656
|
Notes for editors
About Provexis plc
AIM quoted Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.
Fruitflow is a natural, breakthrough ingredient that helps with platelet aggregation. This helps promote normal blood flow and circulation, which in turn benefits cardiovascular health. Fruitflow helps the platelets to circulate freely and smoothly throughout your blood, without sticking to one another or to the blood vessels themselves. Freely flowing blood helps reduce stress on your cardiovascular system.
Fruitflow is a highly concentrated form of bioactives which is lycopene-free and contains over 30 known anti-platelet compounds. Published clinical studies have shown that Fruitflow works to maintain healthy blood flow in a similar way to 75mg aspirin but with a milder and reversible action; Fruitflow has a similar antiplatelet effect to a single dose of aspirin - but when taken daily, it has none of aspirin's side effects.
The science behind Fruitflow has been validated by leading peer review publications and regulatory authorities. Fruitflow is the only natural antiplatelet to have a health claim approved by the European Food Safety Authority, stating that 150mg of Fruitflow 'helps maintain normal platelet aggregation, which contributes to healthy blood flow'.
Fruitflow has a number of specific health benefits which have been reflected in separate patent filings for the use of Fruitflow in:
· mitigating exercise-induced inflammation;
· managing blood pressure;
· protecting against the adverse effects of air pollution on the body's cardiovascular system. Laboratory work has shown that Fruitflow can reduce the platelet activation caused by airborne particulate matter, such as that from diesel emissions, by approximately one third; and
· conferring health benefits in modulating the gut microbiome of humans, to include a reduction in TMAO, following the completion of a successful human study which is further detailed here www.dsm-firmenich.com/en/businesses/health-nutrition-care/news/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html.
Provexis sells a high quality dietary supplement product containing Fruitflow and Omega-3 from its website www.fruitflowplus.com on a mail order basis. The product is also available to purchase from Amazon.co.uk.
Provexis has been working with BYHEALTH, a circa
The Chinese regulatory system for functional health food ingredients, such as Fruitflow, is governed by the State Administration for Market Regulation (the 'SAMR') and it is based on a defined list of permitted health function claims which brand owners are permitted to use on product labels.
In
The significance of these major developments for Fruitflow in
Provexis was founded in 1999 and is headquartered in
For further information, please visit www.provexis.com and www.fruitflowplus.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a)
|
Name |
|
||||||
|
2
|
Reason for the notification |
|||||||
|
a)
|
Position/status
|
See 1 a) above |
||||||
|
b)
|
Initial notification / Amendment
|
Initial notification |
||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a)
|
Name
|
PROVEXIS PLC |
||||||
|
b)
|
LEI
|
21380042E3Y3N9VZ6N48
|
||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.1p each
ISIN: GB00B0923P27
|
||||||
|
b)
|
Nature of the transaction
|
Grant of options over ordinary shares |
||||||
|
c)
|
Price(s) and volume(s)
|
|
||||||
|
d)
|
Aggregated information - Aggregated volume - Price
|
|
||||||
|
e)
|
Date of the transaction
|
|
||||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE